doi:10.3390/nu13124359
Among patients with T2D who had a prior history of CUD, semaglutide was associated with a lower risk for recurrent CUD diagnosis (medical encounters for CUD diagnosis) compared with non-GLP-1RA anti-diabetes medications for a 12-month follow-up period (13.7% vs
For weight management specifically, comparisons should reference the higher 2.4 mg dose of semaglutide (Wegovy) rather than the 1 mg dose used for diabetes
In addition, to address the potential recruitment bias due to the original study design, we weighted the prevalence of insomnia in this study based on the local epidemiologic data from our previous studies (10% in adults and 6% in adolescents) 31,32 The results are presented in the supplementary Tables 13
Patients may be advised to eat smaller, more frequent meals, avoid high-fat or high-fiber foods, and focus on easily digestible options
Your dermatologist will decide how often to provide the injections